AAREY DRUGS & PHARMACEUTICALS
|
|
BOM : 524412     NSE : AAREYDRUGS     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Apr 16,2025 |
Price(EOD): ₹ 55.53
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 157.71 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AAREY DRUGS & PHARMACEUTICALS | 18.9% | 47.8% | 9.8% |
SUN PHARMACEUTICAL INDUSTRIES | 0.2% | 1% | 6.3% |
DIVIS LABORATORIES | 6.8% | 1.6% | 53.3% |
CIPLA | 4.4% | 2.9% | 4.1% |
TORRENT PHARMACEUTICALS | -0.7% | 4% | 25.1% |
DR REDDYS LABORATORIES | 4.6% | 4.9% | -6.2% |
MANKIND PHARMA | 7.6% | 16.3% | 2.5% |
ZYDUS LIFESCIENCES | -4.4% | -7.5% | -11.1% |
LUPIN | -2.4% | -1.5% | 25.3% |
FUNDAMENTAL ANALYSIS OF AAREY DRUGS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AAREY DRUGS & PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
27.61
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 5.70 Cr
[Latest Qtr - Dec2024 - Standalone Results ] 1.21
P/B Calculated based on Book Value of Rs 130.31 Cr
[Latest Year - Mar2024 - Standalone Results ] 0.27
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
1361% -11% -7% |
SHARE PRICE MOMENTUM OF AAREY DRUGS & PHARMACEUTICALS
AAREY DRUGS & PHARMACEUTICALS vs SENSEX
DEBT OF AAREY DRUGS & PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.24 0.33 0.13 0.23 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AAREY DRUGS & PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AAREY DRUGS & PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
27.24% -40.89% -19.82% -55.01% |
74.94% -18.5% -4.37% -29.68% |
QtrlyTrend |
-4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
AAREY DRUGS & PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about AAREY DRUGS & PHARMACEUTICALS
Is AAREY DRUGS & PHARMACEUTICALS good for long term investment?
As on Apr 16,2025, the Fundamentals of AAREY DRUGS & PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of AAREY DRUGS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AAREY DRUGS & PHARMACEUTICALS UnderValued or OverValued?
As on Apr 16,2025, AAREY DRUGS & PHARMACEUTICALS is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS ?
As on Apr 16,2025, the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS is Rs. 59.57 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3.80
Fair Value [Median EV / Sales Model] : Rs. 62.41
Fair Value [Median Price / Sales Model] : Rs. 59.57
Estimated Median Fair Value of AAREY DRUGS & PHARMACEUTICALS : Rs. 59.57
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.